?-Amyloid BRI Protein (1-34) (reduced) 0.5mg

?-Amyloid BRI Protein (1-34) (reduced) 0.5mg
Product Description

Chinese peptide co provides wide range of products which includes ?-amyloid bri protein (1-34) (reduced) 0.5mg. It belongs to?-amyloids and related peptides category. Contact us for more information.

CPC Scientific.Inc

  • US
  • 2015
    On CPHI since
  • 500 - 999
    Employees
Company types
CMO/CDMO
Specifications
  • Details
    Formula: C173H275N49O52S2; Molecular weight: 3937.6
  • Selling Points
    Brand Name; Experienced Technicians
  • Supplied from
    China

CPC Scientific.Inc

  • US
  • 2015
    On CPHI since
  • 500 - 999
    Employees
Company types
CMO/CDMO

More Products from CPC Scientific.Inc (99)

  • ?-Amyloid (40-1) 0.05mg

    Product ?-Amyloid (40-1) 0.05mg

    Chinese peptide co provides wide range of products which includes ?-amyloid (40-1) 0.05mg. It belongs to?-amyloids and related peptides category. Contact us for more information.
  • ACTH-015A

    Product ACTH-015A

    Cpc provides wide range of products which includes acth-015a. Category: adrenocorticotropic hormones (acth). Contact us for more information.
  • ?-Amyloid / A4 Protein Precusor (APP) (319-335) 1mg

    Product ?-Amyloid / A4 Protein Precusor (APP) (319-335) 1mg

    Chinese peptide co provides wide range of products which includes ?-amyloid / a4 protein precusor (app) (319-335) 1mg. It belongs to?-amyloids and related peptides category. Contact us for more information.
  • ADRM-005A

    Product ADRM-005A

    Cpc provides wide range of products which includes adrm-005a. Category: adrenomedullins. Contact us for more information.
  • ?-Amyloid BRI Precursor277 (89-106) 1mg

    Product ?-Amyloid BRI Precursor277 (89-106) 1mg

    Chinese peptide co provides wide range of products which includes ?-amyloid bri precursor277 (89-106) 1mg. It belongs to?-amyloids and related peptides category. Contact us for more information.
  • ADRM-006A

    Product ADRM-006A

    Cpc provides wide range of products which includes adrm-006a. Category: adrenomedullins. Contact us for more information.
  • ADRM-007A

    Product ADRM-007A

    Cpc provides wide range of products which includes adrm-007a. Category: adrenomedullins. Contact us for more information.
  • ?-Amyloid Dan Protein (1-34) 0.5mg

    Product ?-Amyloid Dan Protein (1-34) 0.5mg

    Chinese peptide co provides wide range of products which includes ?-amyloid dan protein (1-34) 0.5mg. It belongs to?-amyloids and related peptides category. Contact us for more information.
  • ADRM-008A

    Product ADRM-008A

    Cpc provides wide range of products which includes adrm-008a. Category: adrenomedullins. Contact us for more information.
  • ?-Casein (90-95)

    Product ?-Casein (90-95)

    Chinese peptide co provides wide range of products which includes ?-casein (90-95). It belongs toa-casein exorphins category. Contact us for more information.
  • ADRM-009A

    Product ADRM-009A

    Cpc provides wide range of products which includes adrm-009a. Category: adrenomedullins. Contact us for more information.
  • ?-Casein (90-96)

    Product ?-Casein (90-96)

    Chinese peptide co provides wide range of products which includes ?-casein (90-96). It belongs toa-casein exorphins category. Contact us for more information.

CPC Scientific.Inc resources (1)

  • News Terlipressin Formulation with API Manufactured by CPC Scientific Approved for Further Study by the MEB

    SAN JOSE, CA., Feb 1, 2021 /CPCNewswire/ — CPC Scientific Inc. is pleased to announce that the Dutch Medicines Evaluation Board (MEB) has completed its technical review of their client’s drug product and formulation process for Terlipressin. The API provided to the client is manufactured at CPC Scientific’s GMP facility. On January 18, 2021, the MEB granted approval of the drug product and will move to the next phase to review product characterization profiles, specifications, and labels in the Netherlands. The MEB is the Dutch regulatory agency responsible for assessing, monitoring, and promoting the proper use of medicines. After final approval, the drug product will be available for sale in the Netherlands and Germany.